Diligence memo · auto-generated · as of July 2, 2026
Gaingels GC Therapeutics LLC
Gaingels GC Therapeutics LLC looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Gaingels GC Therapeutics LLC operates in Pharma, based in BURLINGTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gaingels GC Therapeutics LLC has raised $340K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $340K on 2023-10-03.
Most recent recorded round closed around 2023-10-03.
Valuation (modeled)modeled
Provath models Gaingels GC Therapeutics LLC at approximately $2.4M (range $190K–$10M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.7 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 25% of Pharma peers (310 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Acanna Therapeutics, Inc., Neural Therapeutics Inc., Insignis Therapeutics Inc., Atacama Therapeutics, Inc., Pharma Acuity, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.